DNYUZ
No Result
View All Result
DNYUZ
No Result
View All Result
DNYUZ
Home News

Patients die waiting for the FDA to approve drugs. This change would help.

November 19, 2026
in News
How to give people quicker access to drugs without sacrificing safety

Neeraj Sood is a senior scholar at the Schaeffer Institute for Public Policy and Government Service at the University of Southern California.

When the Food and Drug Administration approves a drug that later harms patients, the agency faces headlines and congressional hearings. When it delays approval and patients suffer or die while waiting, the FDA is rarely held responsible.

A sensible approval system would even the scales and consider both harms.

Drugs generally go through three phases of clinical trials. Phase I tests for safety in a few dozen people; Phase II tests efficacy and safety in hundreds of patients; and Phase III retests both in thousands. A drug that shows promise in Phase II typically spends about five more years in Phase III and FDA review. During this time, patients can see its promise but can’t get a prescription.

But this doesn’t have to be the case. Congress could design a system that allows patients access to promising drugs earlier without sacrificing the integrity of the review process.

Consider a conditional-approval option for drugs that meet three conditions: A well-designed randomized Phase II trial shows that patients feel, function or survive better; the initial safety profile is acceptable; and a larger randomized confirmatory trial is already enrolling, with a credible plan for completion. Approval would be time-limited, renewed only if the larger trial determines that benefits still outweigh risks.

The FDA already has a narrower version of this idea. Since 1992, its accelerated-approval program has let drugs for serious conditions reach patients early based on a surrogate marker — such as tumor shrinkage — that is “reasonably likely” to predict real benefit, provided the company later confirms it. But only about 10 percent of new drugs have used the program, roughly 80 percent of which were for cancer. Most diseases have no accepted surrogate marker, so patients generally must wait until larger Phase III trials are complete.

Congress should widen that door and let the FDA grant conditional approval after Phase II when the cost of being wrong is low or the cost of waiting is high. The most obvious candidates are drugs for conditions that have no existing treatment or conditions that have inadequate standard therapy. Conditional approval could also include drugs that are add-ons to standard care for serious diseases, giving patients a chance to benefit without giving up treatment that works, and drugs whose effects are evident within weeks — clearer skin, fewer migraines, less pain — so that patients can simply stop using them if they aren’t working.

The evidence standard for such a policy would be relatively high. Accelerated approval rests on surrogate markers, but that doesn’t require the randomized evidence of a Phase II trial. In fact, one study of cancer drugs found that about two-thirds of accelerated approvals rested on trials with no control group.

Today’s approval regime dates to 1962, built in response to the thousands of children born with birth defects due to the anti-nausea drug thalidomide. That crisis spurred Congress to require that drugs show “substantial evidence” of efficacy from “adequate and well-controlled” investigations. That hardened into an expectation of large Phase III trials.

The FDA recently drafted guidance clarifying when one rigorous trial, supported by other evidence, can establish effectiveness. That is a welcome step, but it does not create the broader conditional-approval pathway proposed here, allowing access while a larger trial continues.

Lopsided incentives still influence FDA decisions: When one kind of error is punished and the other is invisible, any agency will drift toward caution. The cost of caution isn’t hypothetical. The University of Chicago economist Sam Peltzman found that the 1962 amendments cut the number of new drugs by more than half, from an average of about 41.5 a year to 16.

Before the 1962 amendment, ineffective drugs tended to lose sales quickly as doctors learned they didn’t work. Conditional approval would revive that discipline. Conditional status would give payers reason to demand prices reflecting the remaining uncertainty. Earlier entry could also spur competition within drug classes and push prices down.

Critics will say this turns patients into guinea pigs. But waiting doesn’t eliminate uncertainty. A Phase III trial shows that a drug works on average, not that it will work for any particular patient. In fact, many top-grossing drugs help only between 4 percent and 25 percent of the people who take them, which means patients and their doctors must learn by trial and error.

Under conditional approval, that learning would start earlier. Some promising Phase II drugs will fail to confirm their benefits or will reveal unacceptable risks. But that is a reason to make approval conditional, not necessarily to deny access until every confirmatory trial is complete.

Even Phase III trials can’t reliably detect every rare or delayed harm. Congress should strengthen the FDA’s Sentinel safety-monitoring system, which already draws on data covering more than 370 million patient identifiers, by funding faster access to hospital and death records and a rapid process for investigating safety signals and restricting use when the evidence warrants.

Liability adds another protective layer: In 2009, the Supreme Court allowed patients to sue brand-name manufacturers that fail to warn of known dangers, giving companies reason to disclose what they know.

None of this means ignoring risk. It means being honest about who should weigh it. A patient who understands that a drug may not work is often better placed than a regulator to decide whether a chance at relief is worth it. Patients shouldn’t have to choose between access and evidence.

Conditional approval can offer earlier access while requiring companies to keep generating rigorous evidence. The FDA’s responsibility is to protect patients from harmful medicines. It should also account for the harm of making them wait for effective therapies.

The post Patients die waiting for the FDA to approve drugs. This change would help. appeared first on Washington Post.

Trump Goon Makes Land Grab for Another South American Nation
News

Trump Goon Makes Land Grab for Another South American Nation

by The Daily Beast
November 19, 2026

A Trump official reportedly suggested that Guyana should turn over some of its mineral-rich land to Venezuela, as the administration ...

Read more
News

Leonid Arkayev Has Died. He Coached Russian Gymnasts to Juggernaut Status.

November 19, 2026
News

Is That Weird Al in ‘GTA 6’? Radio and Music Explained

November 19, 2026
News

Here come the Social Security proposals — choose wisely

November 19, 2026
News

Love and Carjackings in a Video Game

November 19, 2026
Wait, Why Exactly Is It So Bad to Sell AI Chips to China?

Wait, Why Exactly Is It So Bad to Sell AI Chips to China?

November 19, 2026
Come to GTA VI for the crime spree. Stay for the manatee.

Come to GTA VI for the crime spree. Stay for the manatee.

November 19, 2026
How to give people quicker access to drugs without sacrificing safety

Patients die waiting for the FDA to approve drugs. This change would help.

November 19, 2026

DNYUZ © 2026

No Result
View All Result

DNYUZ © 2026